Close Menu

NEW YORK – A little more than a month into its new life as a publicly traded company, sequencing firm Personalis updated investors this week on how customers have been receiving its recently launched comprehensive tumor and immune profiling assay ImmunoID NeXT, as well as how its efforts to develop an exome-wide liquid biopsy product are proceeding.

Launched through an early-access program that began in January, NeXT combines exome-wide analysis of DNA and RNA with interrogation of the tumor microenvironment in a single FFPE sample.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.